769 million. That's how many lives our products touched in 2020. And while we're proud of that fact, in this world of digital and technological transformation, we must also ask ourselves this: how can we continue to improve and extend even more people's lives?
The Mergers and Acquisitions ("M&A") Senior Finance Analyst is responsible for modeling and evaluating potential M&A target companies/assets for Novartis Group and will also provide support to projects in exploratory, due-diligence or execution stages.
The M&A Senior Finance Analyst will be part of the Corporate Group M&A team at Novartis. The M&A team supports Novartis management in assessing external innovation and deal opportunities to ensure Novartis retains its position as a leading medicines company. The M&A team is critical as externally sourced assets represent more than 50% of Novartis' current pipeline and sales and Novartis has been a leading pharma acquiror in recent years. The role is high and dynamic visible role within Novartis with an opportunity for growth.
Your responsibilities: - Finance. Act as the center of excellence for flawless financial evaluation and analysis of M&A projects, developing financial models and testing/challenging underlying assumptions of business cases. - Collaboration. Be a valuable partner for corporate functions (Group BPA/Tax/FRA...), Division/Business Units, Global Drug Development, NIBR, NTO to understand and challenge assumptions and valuation drivers. - Execution. Provides support to M&A Finance Head on valuation and project approval, and to the broader M&A and project team on strategic assessment, due diligence and execution.